SCHEMBL6792721

SCHEMBL6792721

CCCCN(CCCC)c1ccc(/C=C2\SC(=S)N(CCS(=O)(=O)NC(=O)C(F)(F)F)C2=O)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ FFAR1 O14842 1/20 0.44
▸ MYC P01106 1/20 0.44
▸ MAX P61244 1/20 0.44
▸ ALDH1A1 P00352 4/20 0.44
▸ MAOA P21397 1/20 0.44
▸ MAOB P27338 1/20 0.44
▸ PAX8 Q06710 1/20 0.43
▸ MEN1 O00255 5/20 0.43
▸ KMT2A Q03164 5/20 0.43
▸ MAPT P10636 4/20 0.43
▸ NCOA3 Q9Y6Q9 3/20 0.43
▸ GPR35 Q9HC97 3/20 0.43
▸ POLB P06746 2/20 0.43
▸ XBP1 P17861 1/20 0.43
▸ MAPK1 P28482 1/20 0.43
▸ HPGD P15428 1/20 0.43
▸ RAB9A P51151 2/20 0.42
▸ TDP1 Q9NUW8 2/20 0.42
▸ PTPN12 Q05209 2/20 0.42
▸ PTPN7 P35236 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6792723 1.00 FFAR1 (0.44) FFAR1MYCMAXALDH1A1MAOA
SCHEMBL6792673 0.97 FFAR1 (0.44) FFAR1MYCMAXALDH1A1MAOA
SCHEMBL6792672 0.97 FFAR1 (0.44) FFAR1MYCMAXALDH1A1MAOA
SCHEMBL6790715 0.89 MCHR1 (0.43) FFAR1MYCMAXALDH1A1MAOA
SCHEMBL6790713 0.89 MCHR1 (0.43) FFAR1MYCMAXALDH1A1MAOA
SCHEMBL6793247 0.89 ALDH1A1 (0.49) FFAR1MYCMAXALDH1A1MAOA
SCHEMBL6793256 0.89 ALDH1A1 (0.49) FFAR1MYCMAXALDH1A1MAOA
SCHEMBL6788442 0.87 FFAR1 (0.50) FFAR1MYCMAXALDH1A1MEN1
SCHEMBL6788437 0.87 FFAR1 (0.50) FFAR1MYCMAXALDH1A1MEN1
SCHEMBL6786181 0.87 PAX8 (0.47) ALDH1A1MAOAPAX8MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1192144-A1 RHODANINE DERIVATIVES AND THEIR USE IN INHIBITING AND IMAGING AMYLOIDS WARNER-LAMBERT COMPANY (US) 2002-04-03 — — EP claimed
WO-2000076988-A1 RHODANINE DERIVATIVES AND THEIR USE IN INHIBITING AND IMAGING AMYLOIDS WARNER-LAMBERT COMPANY (US) 2000-12-21 — — WO claimed
US-20040197268-A1 Method of imaging amyloid deposits using substituted rhodanine derivatives AUGELLI-SZAFRAN CORINNE ELIZAB (US) 2004-10-07 — — US disclosed
EP-1192144-A1 RHODANINE DERIVATIVES AND THEIR USE IN INHIBITING AND IMAGING AMYLOIDS WARNER-LAMBERT COMPANY (US) 2002-04-03 — — EP disclosed
WO-2000076988-A1 RHODANINE DERIVATIVES AND THEIR USE IN INHIBITING AND IMAGING AMYLOIDS WARNER-LAMBERT COMPANY (US) 2000-12-21 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040197268-A1 Method of imaging amyloid deposits using substituted rhodanine derivatives APP, PSEN1, PSEN2 FFAR1 2567/4885MYC 4528/4885MAX 2630/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback